13 reports of this reaction
1.4% of all BUTENAFINE HYDROCHLORIDE reports
#12 most reported adverse reaction
PRODUCT ADMINISTERED AT INAPPROPRIATE SITE is the #12 most commonly reported adverse reaction for BUTENAFINE HYDROCHLORIDE, manufactured by Bayer Healthcare LLC.. There are 13 FDA adverse event reports linking BUTENAFINE HYDROCHLORIDE to PRODUCT ADMINISTERED AT INAPPROPRIATE SITE. This represents approximately 1.4% of all 901 adverse event reports for this drug.
Patients taking BUTENAFINE HYDROCHLORIDE who experience product administered at inappropriate site should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT ADMINISTERED AT INAPPROPRIATE SITE is a less commonly reported adverse event for BUTENAFINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to product administered at inappropriate site, the following adverse reactions have been reported for BUTENAFINE HYDROCHLORIDE:
The following drugs have also been linked to product administered at inappropriate site in FDA adverse event reports:
PRODUCT ADMINISTERED AT INAPPROPRIATE SITE has been reported as an adverse event in 13 FDA reports for BUTENAFINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT ADMINISTERED AT INAPPROPRIATE SITE accounts for approximately 1.4% of all adverse event reports for BUTENAFINE HYDROCHLORIDE, making it a notable side effect.
If you experience product administered at inappropriate site while taking BUTENAFINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.